Oncology

HR+/HER2- Metastatic Breast Cancer

Advertisement

Conference Reporter® in HR+/HER2- Metastatic Breast Cancer to Cover Key Topics Being Presented at ESMO 2025

conference reporter by William J. Gradishar, MD, FACP; Sara M. Tolaney, MD, MPH
Overview
<p><em>Conference Reporter </em>delivers health care providers with insights from key thought leaders on exciting news presented at major medical conferences, in a concise and timely format. <em>Conference Reporter</em> will feature community-selected experts and topics in HR+/HER2- Metastatic Breast Cancer presented at this year’s European Society for Medical Oncology Congress.</p>

VIEW THE TOPICS: 

  • Later-Line Treatment for Metastatic HR+/HER2- Breast Cancer
  • Recent Data With CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer
  • Special Considerations in Treating Older Adults With Metastatic Breast Cancer
  • Updates on Metastatic HR+/HER2- Breast Cancer: Highlights From ESMO


This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the European Society for Medical Oncology Congress.

ESMO 2025

October 17–21, 2025

Berlin, Germany

Link to Registration

Author Photo
Profile

William J. Gradishar, MD, FACP

Director, Maggie Daley Center for Women’s Cancer Care
Betsy Bramsen Professor of Breast Oncology
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL

Author Photo
Profile

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor, Department of Medicine
Harvard Medical School
Boston, MA

Advertisement